Кларитромицин: настоящее и будущее

кларитромицин

1. Kees F, Wellembofer М., Grobecker Н. Serum and cellular pharmacokinetics of clarithromycin 500 mg oid and 250 mg bid in volunteers. Infection 1995; 23: 168-172.

2. Каманин Е.И., Егорова О.А. Острый средний отит у детей: клиническое значение и антибактериальная терапия. Клин. антимикроб. химиотер. 2000; 2 (2): 57-62.

3. Choi Y.S., Choo MJ. Evaluation of the efficacy and safety of clarithromycin in the treatment of outpatients with acute maxillary sinusitis. In: The 3rd International conference on the macrolides, azalides and streptogramins. Lisbon; 1996. abstr. 13.05.

4. Holm S.E. Reasons for failures in penicillin treatment of streptococcal tonsillitis and possible alternatives. Pediatr. Infect. Dis. J. 1994; 13 (suppl. 1): 66-70.

5. Brook I, Gober A.E. Role of bacterial interference and β-lacta-mase-producing bacteria in the failure of penicillin to eradicate Group A streptococcal pharyngotonsillitis. Arch. Otolaryngol. Head Neck Surg. 1995; 121 (12): 1405-1409.

6. Kaplan E.L., Gooch W.M., Notario G.E. et al. Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin). Clin. Infect. Dis. 2001; 32: 1798-1802.

7. Peters D.H, Clissold S.P. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1993; 44 (1): 117-164.

8. Rico Mendez F.G., Sanchez J., Abate E. et al. Efficacy and safety of clarithromycin in the treatment of ambulatory patients with acute bacterial exacerbations of chronic bronchitis. In: 3rd International conference macrolides azalides streptogramins. Lisbon; 1996. abstr. 11.07.

9. Adam D. Clarithromycin 250 mg b.i.d. for 5 of 10 days in the treatment of adult patients with purulent bronchitis. Infection 1993; 21 (4): 265-271.

10. Notario G, Reitmeyer R, Horn R. Clarithromycin 250 mg BID in the treatment of patients with acute exacerbation of chronic bronchitis with COPD. In: 3rd International conference macrolides, azalides streptogramins. Lisbon; 1996. abstr. 11.06.

11. Spiritus E. Clarithromycin in the treatment of bacterial exacerbations of chronic bronchitis in smokers. Curr. Ther. Res. 1995; 56: 16-23.

12. Ziering W., McElvaine P. Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. Infection 1998; 26 (1): 68-75.

13. Leophonte P., Chauvin J.P. Safety and efficacy of clarithromycin compared with cefpodoxim proxetil in the treatment of acute exacerbation of chronic obstructive pulmonary disease. In: 3rd International conference macrolides azalides streptogramins. Lisbon; 1996. abstr. 11.05.

14. Anzueto A., Niederman M.S., Tillotson G.S. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis study Group. Clin. Ther. 1998; 20 (5): 885-900.

15. Lipsky B.A., Unowsky J., Zhang H. et al. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin. Clin. Ther. 1999; 21 (6): 954-965.

16. Wilson R., Kubin R., Ballin J. et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 1999; 44 (4): 501-513.

17. Hoffken G., Meyer H.P., Winter J. et al. The efficacy and safety of two oral moxifloxacin regimens to oral clarithromycin in the treatment of community-acquired pneumonia. Respir. Med. 2001; 95: 553-564.

18. Чучалин А.Г., Синопальников А.И., Яковлев С.В. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. (Пособие для врачей). Клин. микробиол. антимикроб. химиотер. 2003; 5 (3): 198-224.

19. Labro М.Т. Antiinflammatory activity of macrolides: a new therapeutic potential? J. Antimicrob. Chemother. 1998; 41 (suppl. B): 37-46.

20. Labro M.T. Macrolide antibiotics: current and future uses. Expert Opin Pharmacother. 2004; 5 (3): 541-550.

21. Basyigit I., Yildiz F., Ozkara S.K. et al. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann. Pharmacother. 2004; 38 (9): 1400-1405.

22. Tagaya E., Tamaoki J., Kondo M. et al. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002; 122 (1): 213-218.

23. Garey K.W., Rubinstein I., Gotfried M.H. et al. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 2000t 118 (6): 1826-1827.

24. Kostadima E., Tsiodras S., Alexopoulos E.I. et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur. Respir. J. 2004; 23 (5): 714-717.

25. Hatippglu J. Rubinstein I. Low-dose, long-term macroiide therapy in asthma: An overview. Clin. Mol. Allergy 2004; 2(1): 2-4.

26. Saviola G. Abdi All L. Rossini P. et al. Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs: an open, uncontrolled pilot study. Clin. Exp. Rheumatol. 2002; 20 (3): 373-378.

27. Saviola G., Abdi Ali L., Shams Eddin S. et al. Clarithromycin in adult-onset Still's disease. Case report with a 1-year follow-up. Clin. Exp. Rheumatol. 2004; 22 (3): 379-379.

28. Сазыкин Ю.О., Крестьянова И.Н., Иванов В.П. Кларитромицин и химиотерапия опухолей Антибиотики и химиотер. 2000; 45 (11): 3-5.

29. Guay D.R.P., Patterson D.R., Seipman N. et al. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Safety 1993; 8 (5): 350-364.

30. Craft J.C., Siepman N. Overview of the safety profile of clarithromycin suspension in pediatric patients. Pediatr. Infect. Dis. J. 1993; 12 (suppl.): 142-147.

31. Bensoa C.A., Williams P.L., Crohn D.L. et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized double-blind placebo-controlled trial. J. Infect. Dis. 2000; 181: 1289-1297.

32. Pai M.P, Graci D.M., Amsden G.W. Macrolide drug interactions: an update. Ann. Pharmacother. 2000; 34: 495-513.

33. Яковлев В.П. Новый макролидный антибиотик кларитромицин. Клин. антимикроб. химиотер. 1999; 2: 56-61.

34. Zhanel G.G., Dueck М, Hoban D.J. et al. Review of macrolides and ketolides: focus an respiratory tract infections. Drugs 2001; 61 (4): 443-498.

35. Yang H.S., Kim Y.J., Kim C.G. Clinical efficacy of clarithromycin in the treatment of acute maxillary sinusitis. In: The 3rd International conference on the macrolides, azalides and strep-togramins. Lisbon; 1996. abstr. 13.06.

36. Marchi E. Comparative efficacy and tolerability of clarithromycin and amoxicillin in the treatment of outpatient with acute maxillary sinusitis. Curr. Med. Res. Opin.1990; 12: 19-24.

37. Karma P, Pukander J, Penttila M. et al. The comparative efficacy and safety of clarithromycin and amoxicillin in the treatment of outpatients with acute maxillary sinusitis. J. Antimicrob. Chemother. 1991; 27 (suppl. A): 83-90.

38. Calhoun K.H., Hokanson J.A. Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Arch. Fam. Med. 1993; 2 (8): 837-840.

39. Dubois J, Saint-Pierre C., Tremblay C. Efficacy of clarithromycin vs. amoxiciilln/clavulanate in the treatment of acute maxillary sinusitis. Ear Nose Throat J. 1993; 72 (12): 804-810.

40. Gehanno P, Barry B, Chauvin J.P. et al. [Clarithromycin versus amoxicillin-clavulanic acid in the treatment of acute maxillary sinusitis in adults]. Pathol.Biol. (Paris) 1996; 44 (4): 293-297.

41. Lasko B, Lau C.Y., Saint-Pierre C. et al. Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicenter. double-blind, randomized study. The Canadian Sinusitis Study Group. J. Intern. Med. Res. 1998; 26 (6): 281-291.

42. Stefansson P, Jacovides A., Jablonicky P. et al. Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis. Rhinology 1998; 36 (4): 173-178.

43. Clifford K, Huck W, Shan M. et al. Double blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis infection study group. Ann.Otol. Rhinol. Laryngol. 1999; 108 (4): 360-377.

44. Henry D.C., Moller D.J.Jr, Adelglass J. et al. Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group. Clin. Ther. 1999; 21 (2): 340-352.

45. Levenstein J.H. Clarithromycin versus penicillin V in the treatment of streptococcal pharyngitis. J. Antimicrob. Chemother'. 1991; 27 (suppl. A): 67-74.

46. Bachand R.T.Jr. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 1991; 27 (suppl. A): 91-100.

47. Stein G.E., Christensen S., Mummaw N. Comparative study of clarithromycin and penicillin V in the treatment of streptococcal pharyngitis.. Eur. J. Clin. Microbiol. Infect. Dis. 1991; 10 (11): 949-953.

48. Still J.G., Hubbard W.C., Poole J.M. et al. Comparison of clarithromycin and penicillin VK suspensions in the treatment of children with streptococcal pharyngitis and review of currently available alternative antibiotic therapies. Pediatr. Infect. Dis. J. 1993; 12 (suppl. 3): 134-141.

49. Padilla N., Figueroa R., Munos M. Analysis of clarithromycin and propicillin in the management of streptococcal pharyngoton-sillitis in children. Clin. Drug Invect. 1999; 18 (3): 183-188.

50. Kearsley N.L., Campbell A., Sanderson A.A. et al. Comparison of clarithromycin suspension and amoxicillin syrup for the treatment of children with pharyngitis and/or tonsillitis. Br. J. Gen. Pract. 1977; 51 (3): 133-137.

51. Scaglione F. Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis. Curr. Med. Res. Opin. 1990; 12: 25-33.

52. Padilla N. Diaz R., Munos M. et al. Streptococcal pharyngo-tonsillitis in children: management with clarithromycin, azithromycin and propicillin. In: 5th International conference macrolides azalides streptogramins. Seville; 2000. abstr. 6.15.

53. Padilla N., Figueroa R., Del Rosario M. et al. Management of pediatric streptococcal pharyngotonsillitis: a comparative analysis of clarithromycin. In: 2nd European congress chemotherapy 7th Biennale conference antimicrobial agents chemotherapy. Hamburg; 1998. abstr. M.201.

54. Craft J.C., Aynilian G., Cox S. Clarithromycin in the treatment of community-acquired pneumonia due to M. pneumoniae in adult and pediatric patients. In: 3rd International conference macrolides azalides streptogramins. Lisbon; 1996. abstr.2.15.

55. Hatipoglu O.N., Tasan Y. A comparative efficacy and safety study of clarithromycin, roxithromycin and erythromycin stearate in mild pneumonia. Yonsei Med. J. 2000; 41 (3): 340-344.

56. Straneo G., Scarpazza G. Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia. J. Intern. Med. Res. 1990; 18 (2): 164-170.

57. Genne D., Siegrist H.H., Humair L. et al. A comparative analysis of clarithromycin iv and amoxicillin-clavulanic acid iv in the treatment of community-acquired pneumonia. In: 4th International conference macrolides azalides streptogramins ketolides. Barcelona; 1998. abstr.10.16.

58. Fogarty C., Grossman C., Williams J.W. et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect. Med. 1999; 16 (1): 748-753.

59. Ramirez J., Unowsky J., Talbot G. et al. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther. 1999; 21 (1): 103-117.

60. Mathers Dunbar L., Hassman J., Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin. Ther. 2004; 26 (1): 48-62.